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Abstract
Background: Clopidogrel is a prodrug that undergoes in vivo bioactivation to show its antiplatelet effects. Recent studies
have shown that cytochrome P450 (CYP), ATP-binding cassette transporters (ABCB1), and paraoxonase-1 (PON1) play crucial
roles in clopidogrel bioactivation. Here, we aim to determine the effects of genetic polymorphisms of CYP (CYP 2C19*2, CYP
2C19*3, and CYP 2C19*17), ABCB1 (ABCB1 3435C.T, ABCB1 129T.C, and ABCB1 2677G.T/A), and PON1 (PON1 Q192R, PON1
L55M, and PON1 108C.T) on the development of stent thrombosis (ST) in patients receiving clopidogrel after percutaneous
coronary intervention (PCI).
Methods and Results: We evaluated the incidence of ST (0.64%) in 4964 patients who were recruited in the CAPTAIN
registry (Cardiovascular Atherosclerosis and Percutaneous TrAnsluminal INterventions). The presence of genetic
polymorphisms was assessed in 20 subjects who developed ST after aspirin and clopidogrel therapy and in 40 age- and
sex-matched control subjects who did not develop ST, which was documented after 9 months of angiographic follow-up. ST
was acute in 5 subjects, subacute in 7, late in 7, and very late in 1. The presence of CYP 2C19*2 allele was significantly
associated with ST (adjusted odds ratio [ORadj]: 4.20, 95% confidence interval [CI], 1.263–9.544; P=0.031). However, genetic
variations in PON1 and ABCB1 showed no significant association with ST.
Conclusion: We conclude that in a Taiwanese population, PON1 Q192R genotype is not associated with ST development
after PCI. However, the presence of CYP 2C19*2 allele is a risk factor for ST development after PCI.
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Introduction
Dual antiplatelet therapy with aspirin and clopidogrel, an
adenosine diphosphate (ADP)-P2Y12 receptor antagonist, has
become the standard treatment for patients with coronary artery
disease (CAD) who undergo percutaneous coronary intervention
(PCI) with stenting [1,2]. However, one of the shortcomings of
clopidogrel therapy is high interindividual variability of its
antiplatelet response [3,4,5]. Inadequate platelet inhibition may
result in stent thrombosis (ST) and increase the frequency of
cardiovascular events [6,7,8]. Clopidogrel is a prodrug that
requires bioactivation, i.e., in vivo conversion into an active
metabolite, to show its antiplatelet effects. Pharmacokinetic and
pharmacodynamic studies have shown that the bioconversion of
clopidogrel is a 2-step process and is mediated by different
enzymes such as ATP-binding cassette transporters (ABCB1),
hepatic cytochrome P450s (CYPs), and esterase paraoxonase-1
(PON1) [9].
Previous studies in young healthy volunteers receiving clopido-
grel have shown that a loss-of-function mutation in CYP, which
yields the CYP 2C19*2 allele, is associated with a marked decrease
in platelet responsiveness to clopidogrel [10]. Other studies have
shown that the presence of CYP 2C19*2 is significantly associated
with a low rate of clopidogrel bioactivation [11,12,13]. Clinical
studies conducted in a large group of patients with cardiovascular
conditions who underwent PCIs have also confirmed that CYP
2C19*2 is associated with diminished clopidogrel responsiveness
and increased frequency of major adverse cardiovascular events,
such as recurrent myocardial infarction, ST, and long-term
mortality [14,15,16,17,18].
However, the CYP 2C19 polymorphisms are only partly
responsible for the low rates of clopidogrel bioactivation and its
role in cardiovascular outcome is still controversial [19]. Previous
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enzymes, which contribute to clopidogrel bioactivation [20],
ABCB1, which modulates clopidogrel absorption [21], and
PON1, may play major roles in clopidogrel metabolism.
PON1 is an arylesterase found in the liver and is involved in
cell-mediated oxidation of high- and low-density lipoproteins
(HDL and LDL) and inhibition of atherosclerotic processes.
Previous studies revealed a controversial associated between
PON1 polymorphism and coronary artery disease [22,23]. A
recent study showed that a common PON1 polymorphism,
Q192R, is associated with clopidogrel bioactivation [24]. Bouman
et al. showed that PON1 is the rate-limiting enzyme in the second
step of clopidogrel bioactivation, namely, hydrolytic cleavage of 2-
oxo-clopidogrel to form the active thiol metabolite. They
performed a case-cohort study of 112 individuals and showed
that the PON1 Q192R polymorphism, rather than CYP 2C19, is
the major determinant of clopidogrel bioactivation.
Recent studies do not associate platelet responsiveness and the
risk of ST development with PON1 Q192R polymorphism
[25,26,27,28]. The reason for the different results obtained in
various studies on the influence of PON1 in clopidogrel
bioactivation is unclear. We hypothesize that this could be
because of the differences in the ethnicity and genetic background
of the study subjects. There might be some differences in PON1 or
CYP genotype distribution between Asian and Caucasian popu-
lations [29,30]. Because different genotype prevalences can lead to
different clinical effects, we investigated the effects of gene
polymorphisms of PON1 (PON1 Q192R, PON1 L55M, and
PON1 108C.T), ABCB1 (ABCB1 3435C.T, ABCB1 129T.C,
and ABCB1 2677G.T/A), and CYP (CYP 2C19*2, CYP 2C19*3,
and CYP 2C19*17) on the development of ST in Taiwanese
patients receiving clopidogrel after PCI.
Materials and Methods
Ethics Statement
Written informed consent was obtained from 26 patients with
ST and from 40 patients who served as controls. The study was
approved by the Chang Gung Medical Foundation Institutional
Review Board and conforms to the ethical guidelines of the
Helsinki declaration.
Study Population and Study Principle
Since November 1995, we have been registering CAD patients
in the CAPTAIN registry (Cardiovascular Atherosclerosis and
Percutaneous TrAnsluminal INterventions). To date, 4964
patients have been enrolled in the registry. We enroll only those
patients who have undergone PCI with stenting and have been
followed up regularly at the outpatient clinic. The overall follow-
up rate is 72%. Long-term follow-up data up to June 2011 were
obtained from the outpatient clinics.
For this study, we screened the data of ST patients from the
CAPTAIN registry. These definition of ST complied with the
consensus criteria definition by the Academic Research Consor-
tium (ARC), and the cases of ST were further classified as acute
(within 24 h after stent implantation), subacute (1–30 days), late
(.30 days to 1 year) and very late (.1 year) [31]. We also
screened and analyzed the data of age-, gender-, and risk factor-
matched subjects without ST from the registry. PCI and post-PCI
treatment procedures complied with current standard guidelines
[1].
The patients in the normal control Han Chinese and Caucasian
groups were randomly selected from the Cell and Genome Bank in
Taiwan [32].
Genotyping
Blood sampling was performed after PCI. DNA was extracted
from 5 mL of blood using DNeasy blood kit (Qiagen) according to
the manufacturer’s instructions. Sequencing of PON1 Q129R
(rs662), CYP 2C19*2 (rs4244285), CYP 2C19 *3 (rs4986893),
CYP 2C19*17 (rs12248560), and ABCB1 C3435T (rs1045642)
was performed with a TaqMan assay by using an ABI Prism
Sequence Detector 7000 (Applied Biosystems) according to the
manufacturer’s protocols. Hardy–Weinberg equilibrium within
each ethnic group was tested and was found to be nonsignificant
for all gene polymorphisms (P.0.05). The genotyping results were
reconfirmed by performing polymerase chain reaction (PCR)
analysis and direct sequencing. The overall error rate was found to
be less than 1%.
Statistical Analysis
All variables are presented as mean 6 standard deviation (SD)
values and counts (in percentages). Categorical variables were
compared using the x
2 test. The Kolmogorov–Smirnov test was
used to check for normal distribution of continuous data.
Continuous variables were evaluated using the Student’s t-test or
one-way analysis of variance (ANOVA), as appropriate. Binary
and polychotomous variables were examined using Fisher’s exact
and x
2 tests. A multiple logistic regression model was used to test
whether gene polymorphisms of PON1 and ABCB1 and CYP
2C19*2, CYP 2C19*3, and CYP 2C19*17 were independent
predictors of ST. In addition to PON1 Q192R and CYP 2C19*2,
the other polymorphisms were also considered in the multivariable
model and their details were entered as the number of risk alleles
identified in the patients (0, 1, or 2) and by assuming a codominant
model for the allele effect; all variables that differed (P,0.10)
between ST and control subjects were also included in the
multivariable model. A P value less than 0.05 was considered
statistically significant. All statistical analyses were performed with
Statistical Package for Social Sciences for Macintosh (SPSS for
Mac; version 18; SPSS Institute).
Results
Subjects with Stent Thrombosis in the CAPTAIN Registry
In the CAPTAIN registry, we enrolled 4964 patients who
underwent PCI with stenting from November 1995 to June 2011.
The overall follow-up rate was 72%, and the incidence of ST was
0.64%. There were 32 cases of definite ST as defined by the ARC
criteria among patients in the registry. Among these 32 patients, 6
refused to participate in the study, and 6 died before we could
include them in the study. Thus, 20 ST subjects were enrolled as
the ST group. For the control or non-ST group, we enrolled 40
age- and sex-matched subjects from the registry who had
undergone PCI but did not develop ST, which was angiograph-
ically confirmed during a follow-up period of 9 months. All the
20 ST patients and 40 control patients received clopidogrel
treatment after stent implantation for 9 months without discon-
tinuation. Other P2Y12 antagonists were not used in the
treatment. In 1 patient, ST occurred very late, i.e., 3 months
after the physician recommended the discontinuation of clopido-
grel after the 9-month treatment.
The baseline characteristics of patients of both the ST and non-
ST groups are listed in Table 1. Clinical variables such as age, sex,
hypertension and smoking history were well balanced between the
2 groups.
Among the 20 ST patients, 5 (25%) received BMS and 15 (75%)
received DES. Among the 40 control patients, 10 (25%) received
Paraoxonase-1 and Stent Thrombosis
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coronary dissection in these patients.
Correlation between the Risk of ST Development and
Polymorphisms of PON1, CYP, and ABCB1
Among the 60 patients included in this study, 27 (45%) were
PON1 RR192 homozygous, 25 (41.7%) were QR192 heterozy-
gous, and 8 (13.3%) were QQ192 homozygous carriers (Table 2).
Among the 20 ST patients, 17 (85%) had at least 1 mutant allele of
PON1 Q192R, of which 10 were RR192 and 7 were QR192
carriers. Among the 40 non-ST subjects, 35 (87.5%) were carriers
of at least 1 PON1 mutant allele (17 were RR192 and 18 were
QR192 carriers). There was no significant correlation between the
PON1 Q192R genotype and the risk of ST (Odds ratio [OR], 0.86,
95% confidence interval [CI], 0.372–2.821; P=0.597). No
significant associations were observed between ST development
and the PON1 L55M and PON1 108C.T polymorphisms
(Tables 3).
Regarding the CYP 2C19*2 genotype, 8 of the 60 patients
(13.3%) were *2/*2 homozygous, 23 (38.3%) were wt/*2
heterozygous, and 29 (48.4%) were wt/wt homozygous carriers.
Among the 20 ST patients, 15 (75%) were carriers of at least
1 CYP 2C19*2 mutant allele (4 *2/*2 carriers and 11 wt/*2
carriers). However, only 16 (40%) of the 40 non-ST patients were
carriers of at least 1 CYP 2C19*2 mutant allele (4 *2/*2 carriers
and 12 wt/*2 carriers). There was a significant correlation
between the presence of CYP 2C19*2 variants and risk of ST
development (OR, 4.2 [95% CI, 1.263–9.544]; P=0.031).
Of the 20 ST patients, 5 had acute ST, 7 had subacute ST, 7
had late ST, and 1 had very late ST. The PON1 Q192R mutant
allele carrier rate was 80% (2 RR192 and 2 QR192 carriers) in 5
acute ST patients, 100% (4 RR192 and 3 QR192 carriers) in 7
subacute ST patients, 71.4% (3 RR192 and 2 QR192 carriers) in 7
late ST patients, and 100% (1 RR192 carrier) in 1 very late ST
patient (Table 4). The CYP2C19 mutant allele carrier rate was
80% (2 *2/*2 and 2 wt/*2 carriers) in 5 acute ST patients, 57.1%
(4 wt/*2 carriers) in 7 subacute ST patients, 85.7% (2 *2/*2 and
4 wt/*2 carriers) in 7 late ST patients, and 100% (1 wt/*2 carrier)
in 1 very late ST patient. There was no difference in genotype
distribution of PON1 Q192R and CYP2C19*2 between acute,
subacute, late, and very late ST, with P values of 0.549 and 0.747,
respectively.
There were no significant correlations between the risk of ST
development and the presence of CYP 2C19*3, CYP 2C19*17,
PON1 L55M, PON1 108C.T, ABCB1 C3435T, ABCB1 129T.C,
and ABCB1 2677G.T (Fig. 1). The mutant allele carrier rate for
CYP 2C19*3 was 10% in the ST group and 15% in the non-ST
group, with an OR of 0.83 (95% CI, 0.315–4.451; P=0.577) for
stent thrombosis. The carrier rate for ABCB1 C3435T was 75% in
the ST group and 57.5% in the non-ST group, with an OR of 2.32
(95% CI, 0.853–7.183; P=0.112) for ST. The CYP 2C19*17,
Table 1. Baseline clinical characteristics.
*ST group
Non-ST
group P value
Variable (n=20) (n=40)
Age (mean), y 60.368.9 59.067.5 0.564
Male, n (%) 17 (85%) 30 (75%) 0.384
Hypertension, n (%) 13 (65%) 18 (45%) 0.149
Diabetes mellitus, n (%) 9 (45%) 12 (30%) 0.132
Smoking, n (%) 11 (55%) 17 (42.5%) 0.369
High sensitive
{CRP
(mg/L)
14.2618.9 18.9637.1 0.597
Total cholesterol (mg/dL) 166.2637.2 183.2635.2 0.089
Triglyceride (mg/dL) 157.16115.2 147.6660.6 0.676
Uric acid (mg/dL) 5.761.3 6.261.7 0.243
Ejection fraction (%) 60.9612.4 59.3611.9 0.631
*ST, stent thrombosis.
{CRP, C-reactive protein.
Baseline clinical characteristics of the stent thrombosis and non-stent
thrombosis groups.
doi:10.1371/journal.pone.0039178.t001
Table 2. Genotype distributions in stent thrombosis (ST) and
non-ST groups.
*ST
group
Non-ST
group
Genotypes (n=20) (n=40) Total P value
CYP 2C19*2 *2/*2 (AA) 4 (20%) 4 (10%) 8 (13.3%) 0.038
wt/*2 (GA) 11 (55%) 12 (30%) 23 (38.3%)
wt/wt (GG) 5 (25%) 24 (60%) 29 (48.4%)
CYP 2C19*3 AA 0 0 0 0.591
AG 2 (10%) 6 (15%) 8 (13.3%)
GG 18 (90%) 34 (85%) 52 (86.7%)
CYP 2C19*17 TT 0 0 0 -
CT 0 0 0
CC 20 (100%) 40 (100%) 60 (100%)
PON1 Q192R RR192 10 (50%) 17 (42.5%) 27 (45%) 0.760
QR192 7 (35%) 18 (45%) 25 (41.7%)
QQ192 3 (15%) 5 (12.5%) 8 (13.3%)
PON1 L55M AA 0 0 0 0.309
AT 1 (5%) 2 (5%) 3 (5%)
TT 19 (95%) 38 (95%) 57 (95%)
PON1 108C.T TT 5 (25%) 8 (20%) 13 (21.7%) 0.873
TC 10 (50%) 20 (50%) 30 (50%)
CC 5 (25%) 12 (30%) 17 (28.3%)
ABCB1 C3435T TT 6 (30%) 5 (12.5%) 11 (18.3%) 0.188
TC 9 (45%) 18 (45%) 27 (45%)
CC 5 (25%) 17 (42.5%) 22 (36.7%)
ABCB1 T129C CC 0 0 0 0.509
CT 1 (5%) 4 (10%) 5 (8.3%)
TT 19 (95%) 36 (90%) 55 (91.7%)
ABCB1 G2677T TT 5 (25%) 6 (15%) 11 (18.3%) 0.544
TA 3 (15%) 4 (10%) 7 (11.7%)
TG 6 (30%) 13 (32.5%) 19 (31.7%)
GA 2 (10%) 10 (25%) 12 (20%)
AA 0 2 (5%) 2 (3.3%)
GG 4 (20%) 5 (12.5%) 9 (15%)
*ST, stent thrombosis.
The genotype frequencies of PON1, CYP,a n dABCB1 polymorphisms in the stent
thrombosis (ST) and non-ST groups. A significant difference (P=0.038) in
genotype distribution between the ST and non-ST groups is seen only for CYP
2C19*2 and not for PON1, CYP 2C19*3, CYP 2C19*17, and ABCB1
polymorphisms.
doi:10.1371/journal.pone.0039178.t002
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population were less than 5%; therefore, a larger study population
is required to detect their effects on clopidogrel bioactivation.
Discussion
In this study, we analyzed the effects of gene polymorphisms of
CYP (CYP 2C19*2, CYP 2C19*3, and CYP 2C19*17), ABCB1
(ABCB1 3435C.T, ABCB1 129T.C, and ABCB1 2677G.T/A),
and PON1 (PON1 Q192R, PON1 L55M, and PON1 108C.T) on
the development of ST in patients receiving clopidogrel after PCI
(Fig. 1). Our study shows that the PON1 Q192R genotype is not
associated with ST development after PCI in Taiwanese
population. However, carriers of the CYP 2C19*2 allele showed
an increased risk of ST development after PCI.
Clinical studies conducted in a large group of patients, mainly
Caucasians, have confirmed that CYP 2C19*2 is associated with
diminished clopidogrel responsiveness and increased frequency of
key adverse cardiovascular events, such as recurrent myocardial
infarction, ST, and long-term mortality [14,15,16,17,18]. The
same result was reported by Luo et al. in a Chinese population
[33]. Hence, our results were similar to those of previously
reported studies.
Several recently published studies have failed to find the
relationship between PON1 Q192R polymorphism and antiplatelet
responsiveness of clopidogrel [25,26,27,28,34]. Moreover, the
relationships between PON1 Q192R polymorphism and ST are
still controversial [24,26]. Our study showed that the PON1
Q192R genotype is not associated with ST development after PCI
in a Taiwanese population. This finding is in concordance with the
results of a recent study by Sibbing et al. [26]; they studied a large
cohort of 1524 patients and concluded that the PON1 Q192R
genotype is not associated with the risk of ST after coronary
stenting by comparing 127 ST patients with 1439 controls in the
same registry.
However, these results are different from the results of a recent
study by Bouman et al. [24]. With in vitro metabolomics-profiling
techniques, they identified PON1 as a key enzyme in the
transformation of 2-oxo-clopidogrel to the active thiol metabolite.
In this study, they compared PON1 Q192R genotype frequencies
in 41 ST patients and 71 controls and found significant association
between PON1 Q192R and ST.
The precise reasons for this discrepancy are still unclear. Most
of the patients in the study by Bouman et al. and Sibbing et al.
were Caucasians. Some researchers suggest that the differences in
populations or study design may account for these differences in
outcome [34]. Our study showed a different PON1 Q192R
genotype distribution in the control group (42.5% for RR192,
45% for QR192, and 12.5% for QQ192) as compared with the
control groups reported by Sibbing et al. (8% for RR192, 39% for
QR192, and 53% for QQ192) and Bouman et al. (18% for
RR192, 47% for QR192, and 35% for QQ192). We have
observed that the Taiwanese patients exhibit a high carrier rate for
the PON1 Q192R mutant allele.
Our study among the Han Chinese population showed no
association between PON1 Q192R and ST development. Further,
both PON1 L55M and PON1 108C.T polymorphisms showed no
association with ST development in our study. Therefore, our
study results support the fact that PON1 polymorphisms do not
contribute to ST development in populations with a different
ethnic or genetic background.
Although we did not detect a significant association between
PON1 gene polymorphisms and ST development, we found
differences in the genotype distribution of PON1 and CYP 2C19*2
between Asian and Caucasian populations (Table 5). We
performed the genotyping of 92 Han Chinese and 92 Caucasian
people without CAD. The Han Chinese population showed an
Table 3. Results of multivariable logistic regression for
genotype carriers in predicting stent thrombosis.
Carrier Odds Ratio
*
P value
Variable (95%
{CI)
PON1 Q129R rs662 0.86 (0.372–2.821) 0.597
PON1 L55M rs854560 1 (0.167–5.985) 0.423
PON1 108 rs705379 0.78 (0.23–2.627) 0.686
CYP 2C19*2 rs4244285 4.20 (1.263–9.544) 0.031
CYP 2C19*3 rs4986893 0.83 (0.315–4.451) 0.577
CYP 2C19*17 rs12248560 ––
ABCB1 C3435T rs1045642 2.32 (0.853–7.183) 0.112
ABCB1 129 rs3213619 1.541 (0.15–15.830) 0.341
ABCB1 2677 rs2032582 0.529 (0.14–2.008) 0.763
*Unadjusted odds ratios (ORs): CYP 2C19*2, OR, 4.50 (1.363–14.844), P=0.028;
PON1 Q129R, OR, 0.74 (0.252–2.171), P=0.697; ABCB1 C3435T rs1045642, OR,
2.22 (0.674–7.293), P=0.212.
{CI, confidence interval.
doi:10.1371/journal.pone.0039178.t003
Table 4. Genotype frequencies of acute, subacute, late, and very late stent thrombosis.
Acute Subacute Late Very late P value
Genotypes (n=5) (n=7) (n=7) (n=1)
CYP 2C19*2 *2/*2 (AA) 2
(40%)
0 2 (28.6%) 0 0.549
wt/*2 (GA) 2 (40%) 4 (57.1%) 4 (57.1%) 1(100%)
wt/wt (GG) 1 (20%) 3 (42.9%) 1 (14.3%) 0
PON1 Q192R RR192 2 (40%) 4 (57.1%) 3 (42.8%) 1 (100%) 0.747
QR192 2 (40%) 3 (42.9%) 2 (28.6%) 0
QQ192 1 (20%) 0 2 (28.6%) 0
There was no difference in the genotype distribution of PON1 Q192R and CYP2C19 between acute, subacute, late, and very late ST, with a P value of 0.549 and 0.747,
respectively.
doi:10.1371/journal.pone.0039178.t004
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RR192 and 35.9% for QR192) whereas the Caucasian population
showed a 35.9% carrier rate for the same polymorphism (4.4% for
RR192 and 31.5% for QR192) (Table 4). The Han Chinese
population also showed higher CYP 2C19*2 mutant allele carrier
rate (12% for *2/*2 and 39.1% for wt/*2) than that of the
Caucasian population (2.2% for *2/*2 and 22.8% for wt/*2).
These findings showing significantly high carrier rates for PON1
Q129R and CYP 2C19*2 in the Han Chinese population may
have an important clinical impact [29,30,35,36,37]. The high
PON1 Q129R carrier rate in the Han Chinese population did not
contribute to the rate of ST development. In contrast, the high
carrier rate of CYP 2C19*2 in the Han Chinese population might
have influenced the clopidogrel responses and cardiovascular
outcome and warrant future investigation.
Figure 1. Percentage of mutant allele carriers of CYP 2C19 and PON1 and ABCB1 polymorphisms. Graph showing the percentage of
mutant allele carriers for cytochrome P450 (CYP) and paraoxonase-1 (PON1) and ATP-binding cassette transporter (ABCB1) polymorphisms in stent
thrombosis (ST) group (blue) and non-ST group (red). The carrier percentage for the CYP 2C19*2 mutant allele is significantly different between the ST
and non-ST groups (75% vs. 40%; carrier odds ratio [OR 4.2; 95% confidence interval [CI], 1.263–9.544; P=0.031), with a high carrier percentage in the
ST group.
doi:10.1371/journal.pone.0039178.g001
Table 5. Genotype frequencies in Asian and Caucasian populations.
Normal Han Chinese population Normal Caucasian population
Genotypes (n=92) (n=92)
CYP 2C19*2 *2/*2 (AA) 11 (12.0%) 2 (2.2%)
wt/*2 (GA) 36 (39.1%) 21 (22.8%)
wt/wt (GG) 45 (48.9%) 69 (75.0%)
CYP 2C19*3 AA 0 0
AG 9 (10%) 0 (0%)
GG 83 (90%) 92 (100%)
PON1 Q192R RR192 (GG) 41 (44.5%) 4 (4.4%)
QR192 (AG) 33 (35.9%) 29 (31.5%)
QQ192 (AA) 18 (19.6%) 59 (64.1%)
ABCB1 C3435T AA 13 (14.1%) 30 (32.6%)
AG 45 (48.9%) 42 (45.7%)
GG 34 (37.0%) 20 (31.7%)
The genotype frequencies of CYP, PON1 Q192R, and ABCB1 C3435T in normal Han Chinese population (n=92) and normal Caucasian population (n=92) are shown.
Normal Han Chinese population has a higher CYP 2C19*2 mutant allele carrier rate (12% for *2/*2 and 19% for wt/*2) than that of the Caucasian population (2.2% for *2/
*2 and 22.8% for wt/*2). The Han Chinese population also showed higher PON1 Q192R mutant allele carrier rate (80.1%; 44.5% for RR192 and 35.9% for QR192) than that
in Caucasian population (35.9%; 4.4% for RR192 and 31.5% for QR192).
doi:10.1371/journal.pone.0039178.t005
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Our study has some limitations. We had a limited sample size
(n=20 cases of ST) combined with the limited strength of the case-
control design. Therefore, the identified ST cases in our study may
not represent all ST cases, and we may have introduced a possible
bias when selecting the control group. We did not use
intravascular ultrasound (IVUS) during stent implantation. IVUS
is a useful tool for detecting reduction in stent size and coronary
dissection, which are powerful predictors of ST.
Conclusion
In conclusion, we found that the PON1 Q192R polymorphism
was not associated with the risk of ST development after PCI in a
Taiwanese population. However, the CYP 2C19*2 polymorphism
remained a key risk factor for ST development in patients who had
undergone PCI.
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